Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: June 1, 2011
Last updated: May 17, 2016
Last verified: May 2016

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.

Condition Intervention
Genetic: gene expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: mass spectrometry

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Degree of surface IGF-IR expression in RMS tumor tissue
  • Feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue

Estimated Enrollment: 60
Study Start Date: June 2011
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue.
  • To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue.

OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosis of rhabdomyosarcoma.


  • Diagnosis of rhabdomyosarcoma

    • Alveolar or embryonal rhabdomyosarcoma
  • Available samples from the Cooperative Human Tissue Network (CHTN) bank


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365962

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Suman Malempati, MD Doernbecher Children's Hospital at Oregon Health and Science University
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01365962     History of Changes
Other Study ID Numbers: ARST11B4
COG-ARST11B4 ( Other Identifier: Children's Oncology Group )
NCI-2011-02858 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
ARST11B4 ( Other Identifier: Children's Oncology Group )
Study First Received: June 1, 2011
Last Updated: May 17, 2016

Keywords provided by Children's Oncology Group:
alveolar childhood rhabdomyosarcoma
embryonal childhood rhabdomyosarcoma
previously treated childhood rhabdomyosarcoma
previously untreated childhood rhabdomyosarcoma
recurrent childhood rhabdomyosarcoma

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Sarcoma processed this record on May 25, 2017